AbbVie stock costs EUR 253.70, 0.86 percent below its 52-week high

Published on 10/14/2026 at 16:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 16.99 billion, up 10.20 percent year over year. AbbVie stock costs EUR 253.70 on October 14, 2026, up 2.46 percent versus the Xetra close.

Stock trades 2.46 percent higher

On October 6, 2026, Scotiabank lifted its AbbVie target from USD 280.00 to USD 320.00.
Second-quarter revenue reached USD 16.99 billion, up 10.20 percent year over year.
AbbVie stock costs EUR 253.70 at Lang & Schwarz on October 14, 2026 at 4:52 p.m. CEST, 2.46 percent above the Xetra close of October 13, 2026, and 0.86 percent below the 52-week high.
AbbVie will report third-quarter 2026 results on October 30, 2026, before market open.

Aquarellgemälde der Chicago-Skyline mit Lake Michigan-Spiegelung bei warmem Abendhimmel — AbbVie Inc. US00287Y1091 Aquarellmalerei der Chicago Skyline am Lake Michigan bei warmem Sonnenuntergang, Illustration mit AI erstellt.

AbbVie stock was trading at EUR 253.70 at Lang & Schwarz on October 14, 2026 at 4:52 p.m. CEST, up 2.46 percent versus the Xetra close of EUR 247.60 on October 13, 2026. The price stood 0.86 percent below its 52-week high of EUR 255.90. Scotiabank analyst Louise Chen raised the target from USD 280.00 to USD 320.00 on October 6, 2026, according to Markets Insider.

Second-quarter revenue grows 10.20 percent

AbbVie reported USD 16.99 billion in net revenues for the second quarter of 2026, ended June 30, 2026, up 10.20 percent from the year-earlier quarter. According to TickerScout, diluted earnings per share were USD 2.03 versus USD 0.52 a year earlier, while net earnings attributable to AbbVie reached USD 3.61 billion. The same report attributes the sharp profit increase partly to a smaller fair-value charge and a lower effective tax rate, so the net-income comparison needs that qualification.

Skyrizi generated USD 5.50 billion in second-quarter revenue, up 24.50 percent year over year. That growth gives the stock a measurable operating counterweight to Humira erosion, while the valuation remains elevated relative to the wider pharmaceutical peer group.

Price stays near yearly high

The Lang & Schwarz price was EUR 2.20 below the 52-week high and EUR 98.50 above the 52-week low of EUR 155.20 on October 14, 2026. The 52-week span therefore covered EUR 100.70, with the current quote positioned near its upper boundary. Trading volume in the finance quote was 726 shares against an average of 582.

Valuation and October 30 results

AbbVie carried a market capitalization of EUR 446.1 billion and a price-to-earnings ratio of 78.55 on October 14, 2026. The company will announce third-quarter 2026 results before the market opens on October 30, 2026, according to BioSpace.

The upcoming report matters because the second-quarter revenue growth and the near-record euro quote now meet at a demanding valuation. Scotiabank's USD 320.00 target is 13.42 percent above the USD 282.13 NYSE price available at 10:52 a.m. ET on October 14, 2026, using the same currency for the comparison.

Comparison with peers

As of October 14, 2026, the peer comparison was:

AbbVie Inc.: plus 2.46 percent, P/E 78.55, market capitalization EUR 446.1 billion

Amgen (NASDAQ, USD): plus 3.01 percent, P/E 26.42, market capitalization USD 229.5 billion

Bristol-Myers Squibb (NYSE, USD): plus 1.91 percent, P/E 12.71, market capitalization USD 118.0 billion

Price and trading context

AbbVie stock was trading at EUR 253.70 at Lang & Schwarz on October 14, 2026 at 4:52 p.m. CEST, 2.46 percent above the Xetra close of October 13, 2026 at EUR 247.60. The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.